Uber users in Austin are getting matched with Waymo robotaxis
The two companies officially launched Tuesday the "Waymo on Uber" robotaxi service in Austin as part of a partnership that has deepened in recent months. The launch comes just days before SXSW, the annual tech, music, film, and comedy conference, kicks off in Austin.
Starting today, Uber users who hail a ride may be matched with a Waymo robotaxi. Users will still be able to opt for the human-driven vehicle, and not the robotaxi, according to Uber. And both options will be priced the same.
Waymo and Uber, once bitter rivals, have been on more amiable terms in recent years. Waymo's autonomous vehicles have been available on the Uber app in Phoenix since October 2023. And the two companies expanded the partnership last year with plans to launch a more exclusive "Waymo on Uber" robotaxi service in Austin and Atlanta in 2025. (Atlanta has yet to launch.)
The structure of the "Waymo on Uber" service forecasts how each company envisions its role in the nascent autonomous vehicle industry.
Under the arrangement, Waymo will be responsible for vehicle testing, roadside assistance, and certain aspects of rider support. Uber will manage the fleet services such as vehicle cleaning, maintenance, inspections, charging, and depot operations through a company called Moove Cars, which is rebranding to Avomo. In 2021, Uber acquired a 30% minority interest in the European company Moove Cars — not to be mistaken with Moove, which coincidentally is managing Waymo's AV fleet in Phoenix.
Until 2020, Uber was developing its own autonomous vehicles technology via its Uber ATG business. After several controversies, including a lawsuit with Waymo and a fatal crash involving an autonomous test vehicle, the ride-hailing company divested Uber ATG in a complex deal with Aurora.
Uber eventually settled its suits with Waymo; a few years later the two companies would come together on friendlier terms.
Uber has spent the past couple of years shoring up its position in the emerging robotaxi market by locking in partnerships with companies like Waymo.
Uber has partnered with 14 autonomous vehicle companies that cover ride-hailing, delivery, and trucking — a handful of which are operating commercially. In December, Uber launched robotaxi rides with WeRide in Abu Dhabi. The company also has commercial deals with sidewalk delivery bot companies Avride, Cartken, and Serve Robotics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
6 minutes ago
- Los Angeles Times
LeBron James and Maverick Carter meet with Nikola Jokic's agent about starting a new league
A proposed international league described as the F1 of basketball gained attention over the weekend when Misko Raznatovic, the agent for Denver Nuggets star Nikola Jokic, posted a photo on Instagram of him meeting in shorts and bare feet with LeBron James and the Lakers star's business partner Maverick Carter on a yacht off the coast of the French Riviera. Raznatovic accompanied the photo with an intriguing comment: 'The summer of 2025 is the perfect time to make big plans for the fall of 2026! @kingjames @mavcarter The post triggered speculation that perhaps James and Jokic could team up on either the Lakers or Nuggets, but more likely it suggests James has more than a peripheral interest in the new league. Front Office Sports reported in January that Carter was advising a group of investors trying to raise $5 billion to jump-start the league but that James wasn't involved. That may have changed. So what's the league about? Early discussions are of a touring model with six men's and six women's teams playing in eight cities, none of which are likely to be in the United States. Investors include the Singapore government, SC Holdings, the Saudi Arabian Public Investment Fund, a Macau casino operator, UBS, Skype founder Geoff Prentice and former Facebook executive Grady Burnett, according to the Financial Times. Reports have linked VC firm Quiet Capital, tech investor Byron Deeter and Hong Kong-based Galaxy Entertainment to the effort. Investors are leaning toward not allowing players in the league unless they cut ties with the NBA, making the model somewhat like LIV Golf — the professional circuit funded by (PIF). A better comparison in terms of format and scale might be Formula 1 Racing, which holds 24 races a year across five continents. Raznatovic's involvement would be key. His Belgrade, Serbia, agency BeoBasket has a partnership with Excel Sports Management and represents dozens of top European players, including Clippers center Ivica Zubac. The EuroLeague is currently recognized as the world's second-best basketball circuit, but can't come close to paying players NBA-level salaries. If Raznatovic's social media post is an indication, the new league could launch as soon as the fall of 2026. Until then, fans wanting an alternative to the NBA can check out Ice Cube's tour-based Big3 basketball league, which makes its single stop in Los Angeles on Aug. 9. The LA Riot, coached by Nick Young and starring Dwight Howard and Jordan Crawford, will play the Boston Ball Hogs at the Intuit Dome at 1 p.m. PDT.
Yahoo
9 minutes ago
- Yahoo
Exploring US High Growth Tech Stocks For Potential Portfolio Expansion
As the U.S. stock market navigates a landscape of fluctuating indices and economic indicators, investors are closely monitoring the Federal Reserve's interest rate decisions and major tech earnings reports, which have recently driven optimism despite intermittent setbacks. In this dynamic environment, identifying high growth tech stocks that align with strong corporate earnings and favorable economic data can be an effective strategy for those looking to expand their portfolios amidst evolving market conditions. Top 10 High Growth Tech Companies In The United States Name Revenue Growth Earnings Growth Growth Rating ACADIA Pharmaceuticals 10.44% 23.61% ★★★★★☆ Palantir Technologies 22.52% 30.87% ★★★★★★ Circle Internet Group 30.80% 60.66% ★★★★★★ Workday 11.38% 29.97% ★★★★★☆ Mereo BioPharma Group 51.11% 57.42% ★★★★★★ OS Therapies 38.35% 16.51% ★★★★★☆ RenovoRx 62.57% 63.11% ★★★★★☆ Vanda Pharmaceuticals 27.11% 60.56% ★★★★★☆ Gorilla Technology Group 27.85% 105.48% ★★★★★☆ Aldeyra Therapeutics 41.72% 74.79% ★★★★★☆ Click here to see the full list of 70 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. CuriosityStream Simply Wall St Growth Rating: ★★★★☆☆ Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content across various platforms, with a market cap of $269.50 million. Operations: CuriosityStream generates revenue primarily from its Curiosity Stream segment, which brought in $54.22 million. CuriosityStream, a burgeoning name in the tech-driven entertainment sector, is making significant strides with its innovative streaming service, Curiosity University. This platform has recently expanded into European markets through Amazon Prime Video Channels in Sweden and the UK, blending academic rigor with compelling storytelling to tap into a growing demand for knowledge-rich content. Impressively, CuriosityStream's earnings are projected to surge by 110.8% annually. Moreover, the company has been actively enhancing shareholder value through strategic shelf registration filings totaling $13.77 million and declaring special dividends reflecting robust improvements in cash flow and profitability—a testament to its financial health and forward-looking management strategies. Dive into the specifics of CuriosityStream here with our thorough health report. Assess CuriosityStream's past performance with our detailed historical performance reports. Mereo BioPharma Group Simply Wall St Growth Rating: ★★★★★★ Overview: Mereo BioPharma Group plc is a biopharmaceutical company focused on developing and commercializing therapeutics for oncology and rare diseases across the UK, US, and internationally, with a market cap of $279.84 million. Operations: Mereo BioPharma Group focuses on developing therapeutics for oncology and rare diseases, with operations spanning the UK, US, and international markets. The company's revenue streams are primarily derived from its biopharmaceutical products in these specialized fields. Mereo BioPharma Group, amid a challenging landscape, is steering towards profitability with an anticipated revenue growth of 51.1% per year, significantly outpacing the US market's average of 9%. This growth trajectory is supported by promising developments in their clinical programs, notably the Phase 3 study of setrusumab for osteogenesis imperfecta. Despite a recent increase in net loss to $12.89 million from last year's $8.95 million, Mereo's strategic focus on rare genetic diseases positions it uniquely within the biotech sector. The company's R&D commitment is underscored by its ongoing investment in innovative therapies that address unmet medical needs, setting a foundation for potential future success in a highly specialized market. Unlock comprehensive insights into our analysis of Mereo BioPharma Group stock in this health report. Understand Mereo BioPharma Group's track record by examining our Past report. Vanda Pharmaceuticals Simply Wall St Growth Rating: ★★★★★☆ Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of $276.99 million. Operations: Vanda Pharmaceuticals focuses on developing and commercializing therapies for unmet medical needs, generating revenue primarily from its biotechnology segment, which contributed $201.35 million. Vanda Pharmaceuticals, recently added to the Russell 2000 Defensive Index, is navigating a transformative phase with a projected annual revenue growth of 27.1%. This growth is bolstered by innovative clinical trials like the first-in-human study for VCA-894A targeting Charcot-Marie-Tooth disease, highlighting its strategic pivot towards specialized therapeutic areas. Despite a substantial net loss increase to $29.49 million in Q1 2025 from $4.15 million previously, Vanda's aggressive R&D investment reflects its commitment to addressing rare genetic disorders, potentially reshaping treatment paradigms and driving future profitability expected within three years. Click here and access our complete health analysis report to understand the dynamics of Vanda Pharmaceuticals. Evaluate Vanda Pharmaceuticals' historical performance by accessing our past performance report. Next Steps Click here to access our complete index of 70 US High Growth Tech and AI Stocks. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Ready For A Different Approach? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CURI MREO and VNDA. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Will wine and spirits be hit by US tariffs tomorrow? Even the EU doesn't know
The EU executive has touted the new asymmetric tariff agreement with the Donald Trump administration, announced on Sunday, as a step toward predictability. Yet, less than a day before the US is expected to implement a new tariff ceiling of 15% on EU industrial goods, crucial details for several sectors, including wine and spirits, remain unresolved. Industry stakeholders are still holding out hope for exemptions, but no official list has been released. A Commission spokesperson admitted on Thursday that wine and spirits are likely to be subject to the tariffs. 'It is not our expectation that wine and spirits will be included in the first group of exemptions announced by the US tomorrow,' the spokesperson said. 'We're still negotiating,' they added, noting that both sides are working to finalise a joint statement based on the agreement reached between Commission President Ursula von der Leyen and US President Donald Trump. Securing an exemption for the wine and spirits industry remains a top priority for the EU negotiating team in Brussels. This industry is seen as strategic—especially for France, which, along with Italy, Spain, and Ireland, is actively lobbying for these products to be spared. 'We are continuing to negotiate with the Americans so that, if possible, spirits, perhaps wine, and other sectors can be exempted. It's a work in progress,' said French Economy Minister Éric Lombard in a radio interview on Wednesday. The US and China are the top export markets for European wine and spirits. In France alone, the industry supports nearly 550,000 jobs across its value chain. Chinese tariffs are already impacting the sector, and new US duties would be a further blow. Related Five things we don't know yet about the EU-US trade deal Both EU and US trade officials, along with major industry associations such as the Distilled Spirits Council and the Comité Européen des Entreprises Vins, have advocated for a 'zero-for-zero' tariff arrangement on wine and spirits. However, the EU's negotiating position has weakened, and Brussels no longer has effective leverage over these products. The past ability to threaten retaliatory tariffs on iconic American exports like bourbon or Californian wine often kept EU wine and spirits off the US target list. That option disappeared with the latest agreement reached in Scotland, leaving the EU less inclined to jeopardise the broader deal over a single sector. Adding to the uncertainty, the Commission spokesperson declined to confirm whether tariffs would be imposed as early as Friday, saying only that they had a 'clear understanding' the US intends to proceed via executive order, possibly overnight.
